Perspective Therapeutics (CATX) Projected to Post Quarterly Earnings on Wednesday

Perspective Therapeutics (NYSEAMERICAN:CATX) is expected to be issuing its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Perspective Therapeutics to post earnings of ($0.27) per share and revenue of $0.0910 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:00 PM ET.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. The firm had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.16 million. On average, analysts expect Perspective Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock opened at $3.00 on Wednesday. Perspective Therapeutics has a 12-month low of $1.96 and a 12-month high of $6.16. The company has a 50-day moving average price of $3.17 and a 200 day moving average price of $3.91.

Analysts Set New Price Targets

Several equities analysts have weighed in on CATX shares. Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a report on Tuesday, May 5th. BTIG Research restated a “buy” rating on shares of Perspective Therapeutics in a report on Friday, July 24th. Eight analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $12.62.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. increased its position in shares of Perspective Therapeutics by 184.1% during the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after acquiring an additional 5,475 shares during the last quarter. Aigen Investment Management LP purchased a new stake in shares of Perspective Therapeutics in the 4th quarter valued at approximately $28,000. nVerses Capital LLC purchased a new stake in shares of Perspective Therapeutics in the 4th quarter valued at approximately $31,000. Engineers Gate Manager LP acquired a new position in shares of Perspective Therapeutics in the 4th quarter worth approximately $35,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Perspective Therapeutics in the 4th quarter worth approximately $42,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.